Patent intelligence · US
US 7163700
Amorphous drug beads
Amorphous drug beads
Patent details — US 7163700
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 16, 2007
- Expiration
- Jan 11, 2027
- Applicant
- Capricorn Pharma Inc.
- Claims
- 9
- CPC classes
- A61K, A61K9/14, A61K9/145, A61K9/146
Quick answer
US 7163700 (Amorphous drug beads) is held by Capricorn Pharma Inc.. Status: granted. Granted Jan 16, 2007. Expires Jan 11, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Capricorn Pharma Inc.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K9/14, A61K9/145, A61K9/146, A61K9/5015, A61K9/5026
More from Capricorn Pharma Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11801268
Methods of treating ocular inflammation and chemical injuries of the eye with extracellular vesicles
granted -
US 11759482
Methods and compositions for treating skeletal muscular dystrophy
granted -
US 10695293
Method of preventing or treating radiation-induced dermatitis with extracellular vesicles
granted -
US 10369173
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9884076
Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
granted -
US 9623085
Chimeric natriuretic peptide compositions and methods of preparation
granted -
US 9616107
Therapy for kidney disease and/or heart failure
granted -
US 9314507
Methods of treatment of heart failure with natriuretic peptides
granted
Frequently asked questions
What is US patent 7163700?
US 7163700 (Amorphous drug beads) is held by Capricorn Pharma Inc.. Status: granted. Granted Jan 16, 2007. Expires Jan 11, 2027 (1 year remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7163700?
Capricorn Pharma Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 43 pharmaceutical patents for this assignee.
When does US 7163700 expire?
Our index shows an expiration date of Jan 11, 2027 (1 year from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.